SCHEMBL2483013

SCHEMBL2483013

Clc1cccc(Cl)c1CNCCc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.62
MAPT P10636 1/20 0.62
SIGMAR1 Q99720 5/20 0.52
MPO P05164 1/20 0.51
LMNA P02545 1/20 0.51
BCHE P06276 3/20 0.49
MAPK1 P28482 1/20 0.49
PTPN7 P35236 1/20 0.49
DUSP3 P51452 1/20 0.49
PTPN5 P54829 1/20 0.49
PTPN11 Q06124 1/20 0.49
TAAR1 Q96RJ0 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27228 0.79 GAA (0.95) GAAMAPTSIGMAR1MPOBCHE
SCHEMBL15283274 0.78 GAA (0.76) GAAMAPTSIGMAR1MPOBCHE
SCHEMBL25432637 0.77 GAA (0.91) GAAMAPTSIGMAR1MPOBCHE
SCHEMBL11881258 0.77 GAA (0.91) GAAMAPTSIGMAR1MPOBCHE
Ammonia Solution, Strong SCHEMBL23581968 0.77 GAA (0.91) GAAMAPTSIGMAR1MPOBCHE
Hydrochloric Acid SCHEMBL1983401 0.77 GAA (1.00) GAAMAPTSIGMAR1MPOBCHE
SCHEMBL3272134 0.77 GAA (0.91) GAAMAPTSIGMAR1MPOBCHE
SCHEMBL22495461 0.77 BCHE (0.74) GAAMAPTSIGMAR1LMNABCHE
SCHEMBL8127992 0.77 BCHE (0.74) GAAMAPTSIGMAR1LMNABCHE
SCHEMBL18768843 0.77 CYP1A2 (0.71) GAAMAPTSIGMAR1LMNABCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1017358-B1 REDUCTION OF HAIR GROWTH GILLETTE CO (US) 2004-08-11 EP claimed
EP-1017358-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2000-07-12 EP claimed
US-5939458-A APPLYING AN INHIBITOR OF AMINOACYL-TRNA SYNTHETASE TO THE SKIN GILLETTE COMPANY, THE 1999-08-17 US claimed
WO-1999015136-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 1999-04-01 WO claimed
CN-107106533-B Synergistic composition for treating microbial infections 罗切斯特大学 2020-11-06 CN disclosed
EP-3212183-B1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIV ROCHESTER (US) 2019-10-02 EP disclosed
US-10028931-B2 Synergistic compositions for treating microbial infections UNIVERSITY OF ROCHESTER (US) 2018-07-24 US disclosed
EP-3212183-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS University of Rochester (US) 2017-09-06 EP disclosed
US-20170246139-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIVERSITY OF ROCHESTER (US) 2017-08-31 US disclosed
WO-2016070021-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIVERSITY OF ROCHESTER (US) 2016-05-06 WO disclosed
CN-102348807-B Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system SUTRO BIOPHARMA INC 2015-04-15 CN disclosed
US-8778631-B2 Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system SUTRO BIOPHARMA, INC. (US) 2014-07-15 US disclosed
US-20100184135-A1 MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM SUTRO BIOPHARMA, INC. (US) 2010-07-22 US disclosed
US-20100184134-A1 DUAL CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO SYNTHESIS METHOD SUTRO BIOPHARMA, INC. (US) 2010-07-22 US disclosed
WO-2010081111-A1 MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM SUTRO BIOPHARMA, INC. (US) 2010-07-15 WO disclosed
WO-2010081110-A1 DUAL CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO SYNTHESIS METHOD SUTRO BIOPHARMA, INC. (US) 2010-07-15 WO disclosed
EP-1017358-B1 REDUCTION OF HAIR GROWTH GILLETTE CO (US) 2004-08-11 EP disclosed
EP-1017358-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2000-07-12 EP disclosed
US-5939458-A APPLYING AN INHIBITOR OF AMINOACYL-TRNA SYNTHETASE TO THE SKIN GILLETTE COMPANY, THE 1999-08-17 US disclosed
WO-1999015136-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 1999-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10028931-B2 Synergistic compositions for treating microbial infections RNASE1, RNASEL, RNASEH1 GAA 416/4885MAPT 4406/4885SIGMAR1 2795/4885
US-20170246139-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS RNASE1, RNASEL, RNASEH1 GAA 416/4885MAPT 4406/4885SIGMAR1 2795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.